Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Differences in Characteristics and Outcomes of Central Nervous System Versus Systemic Relapse after First Line Therapy in DLBCL Patients: A Veterans Health Administration (VHA) Study

Blood (2023) 142 (Supplement 1): 5161.

https://doi.org/10.1182/blood-2023-190641

Published: 2023

Journal Articles

Real-World Applications of Guideline Based Diagnostic and Treatment Patterns for Diffuse Large B-Cell Lymphoma within the Veterans Health Administration (VHA)

Blood (2023) 142 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2023-187709

Published: 2023

Journal Articles

Demographics, Treatment Patterns and Survival Outcomes of Follicular Lymphoma in the United States: A National Hospital Based Study with Emphasis on Hispanics

Andrew Ta, Supreet Kaur, Qianqian Liu, Joel Michalek, Adolfo Diaz Duque

Blood (2023) 142 (Supplement 1): 7365.

https://doi.org/10.1182/blood-2023-187288

Published: 2023

Journal Articles

Association between Cytogenetic Risk and Obesity in Patients with Acute Myeloid Leukemia (AML): A Meta-Analysis

Raed Benkhadra, Iuliia Kovalenko, Ekaterina Proskuriakova, Tarek Nayfeh, Michael Auster, Leslie Hassett, Supreet Kaur

Blood (2023) 142 (Supplement 1): 5828.

https://doi.org/10.1182/blood-2023-178245

Published: 2023

Journal Articles

Insights from a Veterans Health Administration Database Analysis: Immune-Related Adverse Effects of Immunotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma

Daniela Urueta Portillo, Sergio A. Vallejo, Michael Mader, Kathleen Franklin, Supreet Kaur, Supreet Kaur

Blood (2023) 142 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2023-175028

Published: 2023

Journal Articles

Breaking Barriers in Classic Hodgkin Lymphoma: Unraveling Disparities between Hispanic and Non-Hispanic Patients Via the National Cancer Database (NCDB)

Daniela Urueta Portillo, Supreet Kaur, Qianqian Liu, Joel Michalek, Adolfo Enrique Diaz Duque

Blood (2023) 142 (Supplement 1): 4449.

https://doi.org/10.1182/blood-2023-189768

Published: 2023

Journal Articles

Retrospective Analysis of Treatment Patterns and Outcomes in Geriatric Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Veterans Health Administration (VHA)

Blood (2023) 142 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2023-190571

Published: 2023

Journal Articles

Survival Outcomes of Diffuse Large B Cell Lymphoma Beyond the Rituximab Era: Comprehensive Analysis of a Veteran Population within the Veterans Health Administration over 11 Years

Blood (2023) 142 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2023-190048

Published: 2023

Journal Articles

Examining Racial Disparities in Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Blood (2023) 142 (Supplement 1): 2398.

https://doi.org/10.1182/blood-2023-184997

Published: 2023

Journal Articles

Match Date-to-Start Date: Engaging Fellows Pre-Training

Supreet Kaur, Shannon Lovelace, Anand Karnad

Blood (2023) 142 (Supplement 1): 7190.

https://doi.org/10.1182/blood-2023-179440

Published: 2023

Journal Articles

Outcomes of Veterans with FMS-like Tyrosine Kinase 3 Mutated (mFLT3) Acute Myeloid Leukemia (AML) Treated with Novel FLT3 Inhibitors (FLT3i) within the Veterans Health Administration (VHA)

Eduardo Garcia, Amy M Horowitz, Kathleen Franklin, Michael Mader, Supreet Kaur

Blood (2023) 142 (Supplement 1): 7414.

https://doi.org/10.1182/blood-2023-173880

Published: 2023

Journal Articles

The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration

Blood (2022) 140 (Supplement 1): 2061–2062.

https://doi.org/10.1182/blood-2022-170576

Published: 2022

Journal Articles

Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

Chase West, Matthew James Butler, Supreet Kaur, Anand Karnad

Blood (2022) 140 (Supplement 1): 5025–5026.

https://doi.org/10.1182/blood-2022-158377

Published: 2022

Journal Articles

Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Blood (2022) 140 (Supplement 1): 9561–9563.

https://doi.org/10.1182/blood-2022-170661

Published: 2022

Journal Articles

Identifying Demographic and Disease Related Differences in Hispanic Vs Non-Hispanic Patients with Post Transplant Lymphoproliferative Disorders

Supreet Kaur, Qianqian Liu, Joel E Michalek, Adolfo Enrique Diaz Duque

Blood (2022) 140 (Supplement 1): 3798–3799.

https://doi.org/10.1182/blood-2022-168259

Published: 2022

Journal Articles

Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant: From Epidemiology to Survival Outcomes from 2000 - 2022

Supreet Kaur, Pankil Shah, Adolfo Enrique Diaz Duque, Dimpy P. Shah

Blood (2022) 140 (Supplement 1): 1074–1075.

https://doi.org/10.1182/blood-2022-170919

Published: 2022

Journal Articles

Identifying Demographic and Disease Related Differences in Hispanic Vs Non-Hispanic Patients with Classical Hodgkin Lymphoma

Abhishek Pandya, Supreet Kaur, Qianqian Liu, Joel E Michalek, Adolfo Enrique Diaz Duque

Blood (2022) 140 (Supplement 1): 13186–13188.

https://doi.org/10.1182/blood-2022-170870

Published: 2022

Journal Articles

Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 5195–5197.

https://doi.org/10.1182/blood-2022-171126

Published: 2022

Journal Articles

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phyllis McKiernan, David S Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MSc, Noa Biran, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Jacquelyn Callahan, RN, Andrea Ortega, RN, Mariefel Vendivil, RN, Supreet Kaur, MD, Marshall McKenna, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2018-99-117313

Published: 2018

Journal Articles

Association of 30 Day Readmission between Psychosocial, Behavioral and Epidemiological Factors in Adult SCD Patients

Aparna Saha, Priti Poojary, Dishita Pandya, Abhishek Kumar, MD, Girish Nadkarni, MD, Supreet Kaur, MD

Blood (2018) 132 (Supplement 1): 1072.

https://doi.org/10.1182/blood-2018-99-117756

Published: 2018

NARROW

Differences in Characteristics and Outcomes of Central Nervous System Versus Systemic Relapse after First Line Therapy in DLBCL Patients: A Veterans Health Administration (VHA) Study

Real-World Applications of Guideline Based Diagnostic and Treatment Patterns for Diffuse Large B-Cell Lymphoma within the Veterans Health Administration (VHA)

Demographics, Treatment Patterns and Survival Outcomes of Follicular Lymphoma in the United States: A National Hospital Based Study with Emphasis on Hispanics

Association between Cytogenetic Risk and Obesity in Patients with Acute Myeloid Leukemia (AML): A Meta-Analysis

Insights from a Veterans Health Administration Database Analysis: Immune-Related Adverse Effects of Immunotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma

Breaking Barriers in Classic Hodgkin Lymphoma: Unraveling Disparities between Hispanic and Non-Hispanic Patients Via the National Cancer Database (NCDB)

Retrospective Analysis of Treatment Patterns and Outcomes in Geriatric Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Veterans Health Administration (VHA)

Survival Outcomes of Diffuse Large B Cell Lymphoma Beyond the Rituximab Era: Comprehensive Analysis of a Veteran Population within the Veterans Health Administration over 11 Years

Examining Racial Disparities in Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Match Date-to-Start Date: Engaging Fellows Pre-Training

Outcomes of Veterans with FMS-like Tyrosine Kinase 3 Mutated (mFLT3) Acute Myeloid Leukemia (AML) Treated with Novel FLT3 Inhibitors (FLT3i) within the Veterans Health Administration (VHA)

The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration

Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Identifying Demographic and Disease Related Differences in Hispanic Vs Non-Hispanic Patients with Post Transplant Lymphoproliferative Disorders

Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant: From Epidemiology to Survival Outcomes from 2000 - 2022

Identifying Demographic and Disease Related Differences in Hispanic Vs Non-Hispanic Patients with Classical Hodgkin Lymphoma

Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Association of 30 Day Readmission between Psychosocial, Behavioral and Epidemiological Factors in Adult SCD Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only